Navigation Links
Biopure Sues National Institutes of Health Official
Date:10/28/2008

Complaint Alleges Defamation, Trade Libel and Intentional Interference with

Prospective Business Advantage

CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it had filed an action for injunctive relief and damages against Charles Natanson, M.D., who co-authored an article and several letters about Hemopure, hemoglobin glutamer-250 (bovine), Biopure's oxygen therapeutic product for human use. The action was filed on October 10, 2008, in the U.S. District Court, District of Columbia. Natanson is senior investigator and head of the anesthesia section of the Critical Care Medicine Department, Clinical Center, of the National Institutes of Health.

The complaint alleges that in publishing the article "Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death" (published by the Journal of the American Medical Association online on April 28, 2008) and writing a number of letters to regulatory authorities in jurisdictions where Biopure is active, Natanson engaged in tortious activity that injured Biopure. Biopure seeks injunctive relief and damages for defamation, trade libel/injurious falsehood and intentional interference with prospective business advantage.

Natanson has not yet filed an answer or any other response.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer -- 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The Company is developing Hemopur
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
6. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
7. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
8. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
9. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
10. International study strengthens case for daily calcium pill
11. Yakima Health Care Leader Tapped for Leadership Post at National Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... sudden, acute episodes of low back pain are not ... pressure, wind direction and precipitation. Findings published in ... American College of Rheumatology (ACR), indicate that the risk ... speed or wind gusts, but was not clinically significant. ... nearly everyone experiences low back pain at some point ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... has been a sharp increase in the number of ... the online, interactive service that allows patients to view ... schedule appointments, and renew prescriptions. , Over a six-year ... each year increased five-fold, while the number of ... to a study by Dr. David Gerber , ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... say, , MONDAY, July 13 (HealthDay News) -- It,s 6 a.m. ... does every morning, lets out a mix of low purr and ... me. , A new British study -- involving participants with names ... learn that this particular cry-purr combination is the most ...
... to Treat Diseases (HTDS.PK) www.htdsmedical.com - subsidiary, ... Co., Ltd for the Haemophilus influenza type b conjugate ... biggest manufacturer of Haemophilus influenza type b conjugate vaccine ... stage for Mellow Hope to be fully authorized to ...
... of cancer-prevention drug, , MONDAY, July 13 (HealthDay News) ... risk for highly aggressive prostate cancer, a new ... to determine the effect of alcohol consumption on prostate ... finasteride (Proscar, Propecia), a drug prescribed to prevent prostate ...
... Previous studies have found that postmenopausal women who ... therapy have increased their risk of developing progestin-accelerated breast ... curcumin, a popular Indian spice derived from the turmeric ... exposure to hormone replacement therapy. "Approximately 6 million ...
... , BALTIMORE,July 13 The National Federation of ... that have made outstanding contributions toward achieving the full integration of ... second annual Dr. Jacob Bolotin Awards honored eight innovators in the ... in Detroit on Wednesday, July 8. , , ...
... , Leading U.S. ... of competitors , , CINCINNATI, ... pharmacy, today announced that it will offer a 30-day supply of ... and prices below that of competitors, including Wal-Mart and Target, HealthWarehouse.com ...
Cached Medicine News:Health News:Cats Purrfect at Getting Needs Met, Study Shows 2Health News:Cats Purrfect at Getting Needs Met, Study Shows 3Health News:Hard To Treat Diseases (HTDS.PK) Agreement With 2nd Largest Vaccine Manufacturer in China Yunnan Walvax Biotech Co 2Health News:Heavy Drinking Linked to Aggressive Prostate Cancer 2Health News:Heavy Drinking Linked to Aggressive Prostate Cancer 3Health News:Asian spice could reduce breast cancer risk in women exposed to hormone replacement therapy 2Health News:National Federation of the Blind Awards $50,000 2Health News:HealthWarehouse.com Announces $3.50 Prescription Drug Program 2
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Mo., Oct. 26 Boehringer Ingelheim, a global pharmaceutical ... business Boehringer Ingelheim Vetmedica, Inc., announced today that it ... significant portion of the Fort Dodge Animal Health business. ... Australia, Canada and South Africa, as well as two ...
... (CTI) (Nasdaq and MTA: CTIC) management will present at the 8th ... held October 28-29, 2009, at the Palace Hotel in San Francisco. ... Pacific Time. The conference will be webcast live with slides and ... at www.celltherapeutics.com . , , ...
Cached Medicine Technology:Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer 2Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer 3
... over 20 years of experience in ... the Life Sciences, the Freedom EVO ... possibilities for expansion according to future ... software, Freedom EVOware, each system is ...
... EVO Clinical is an open platform for clinical ... in deck sizes of 75, 100, 150 ... instrument for your laboratory space and throughput requirements. ... features to allow new applications and to evolve ...
... liquid handling system that ... of up to three ... the same worksurface. Offered ... solutions for targeted applications ...
... The AccelNet Laboratory Automation Network ... clinical chemistry systems, an automated sample ... manager to create a single, powerful ... ideal for laboratories that need a ...
Medicine Products: